Relief Therapeutics Holding SA (SWX:RLF)
2.500
+0.040 (1.63%)
Aug 12, 2025, 4:16 PM CET
Apartment Income REIT Revenue
In the year 2024, Relief Therapeutics Holding had annual revenue of 8.42M CHF with 39.52% growth. Relief Therapeutics Holding had revenue of 3.01M in the half year ending December 31, 2023, a decrease of -9.36%.
Revenue
8.42M
Revenue Growth
+39.52%
P/S Ratio
3.68
Revenue / Employee
271.52K
Employees
31
Market Cap
30.93M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.42M | 2.38M | 39.52% |
Dec 31, 2023 | 6.03M | -48.00K | -0.79% |
Dec 31, 2022 | 6.08M | 2.76M | 83.11% |
Dec 31, 2021 | 3.32M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Lonza Group AG | 7.09B |
Alcon | 8.77B |
Galderma Group AG | 3.73B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Relief Therapeutics Holding News
- 1 day ago - Relief Therapeutics Advances Publication of 2025 Half-Year Report - Accesswire
- 14 days ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 14 days ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire
- 7 weeks ago - Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 - Accesswire
- 2 months ago - Relief Therapeutics Announces Results of Annual General Meeting - Accesswire
- 2 months ago - Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 - Accesswire
- 3 months ago - Relief Therapeutics Publishes 2025 Annual General Meeting Agenda - Accesswire
- 4 months ago - Relief Therapeutics Holding GAAP EPS of -CHF 1.37, revenue of CHF 9.83B - Seeking Alpha